Exact Mass: 555.1489

Exact Mass Matches: 555.1489

Found 34 metabolites which its exact mass value is equals to given mass value 555.1489, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Tiapamil

2-(3,4-dimethoxyphenyl)-2-(3-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}propyl)-1lambda6,3lambda6-dithiane-1,1,3,3-tetrone

C26H37NO8S2 (555.196)

C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

Fiduxosin

5-(4-{13-methoxy-8-oxa-4-azatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien-4-yl}butyl)-12-phenyl-8-thia-3,5,10,13-tetraazatricyclo[7.4.0.0^{2,7}]trideca-1(13),2(7),9,11-tetraene-4,6-dione

C30H29N5O4S (555.194)

Baumycin C1

C28H29NO11 (555.1741)

N-Fructosyl S-(2-carboxypropyl)glutathione

C20H33N3O13S (555.1734)

Annotation level-3

2-Desoxy-[5]adenylsaeure-thymidin-3-ylester|d(TpA)|TA|thymidilyl-(3<*>5)-2-deoxyadenosine|thymidylyl-(3->5)-2-deoxy-adenosine|TpA|TpdA

C20H26N7O10P (555.1479)

4-[4-[[3-[(ethylanilino)sulphonyl]-4-methylphenyl]azo]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzenesulphonic acid

C25H25N5O6S2 (555.1246)

alkali blue 4b

Sodium ((4-((4-amino-m-tolyl)(4-(phenylimino)cyclohexa-2,5-dien-1-ylidene)methyl)phenyl)amino)benzenesulphonate

C32H26N3NaO3S (555.1592)

4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile

C25H23Cl2N7O4 (555.1188)

VER-155008 is an inhibitor of Hsp70, with IC50s of 0.5 μM, 2.6 μM, and 2.6 μM for Hsp70, Hsc70 and Grp7, respectively, and with a Kd of 0.3 μM for Hsp70.

Green 5

C27H27N2O7S2+ (555.126)

S-adenosylglutathione

C20H27N8O9S- (555.1622)

1-[[(4R,5S)-8-bromo-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4S,5S)-8-bromo-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4R,5R)-8-bromo-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4S,5R)-8-bromo-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4R,5S)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4R,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

1-[[(4S,5S)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-3-(2-methoxyphenyl)-1-methylurea

C23H30BrN3O6S (555.1039)

Tiapamil

N-[2-(3,4-Dimethoxyphenyl)ethyl]-3-[2-(3,4-dimethoxyphenyl)-1,1,3 ,3-tetraoxido-1,3-dithian-2-yl]-N-methyl-1-propanamine

C26H37NO8S2 (555.196)

(rel)-AR234960

C27H30FN5O5S (555.1952)

(rel)-AR234960 is an active relative configuration of AR234960. AR234960, a non-peptide MAS (a G protein-coupled receptor) agonist, increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts[1].

OSMI-2

C26H25N3O7S2 (555.1134)

OSMI-2 (Compound 1b) is a cell-permeable O-linked N-acetylglucosamine transferase (OGT) inhibitor. Cells contain a large nuclear pool of partially spliced OGT transcript, and OSMI-2 increases detained intron splicing in cells[1].

2-amino-3-(3,4,5-trihydroxyphenyl)-n-[2-(3,4,5-trihydroxyphenyl)-1-{[2-(3,4,5-trihydroxyphenyl)ethenyl]carbamoyl}eth-1-en-1-yl]propanimidic acid

C26H25N3O11 (555.1489)

2-amino-4-{[2-({2-[(4-amino-4-carboxy-1-hydroxybutylidene)amino]-2-carboxyethyl}disulfanyl)-1-(carboxymethyl-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butanoic acid

C18H29N5O11S2 (555.1305)

(2s)-2-amino-4-{[(1r)-2-{[(2r)-2-{[(4s)-4-amino-4-carboxy-1-hydroxybutylidene]amino}-2-carboxyethyl]disulfanyl}-1-(carboxymethyl-c-hydroxycarbonimidoyl)ethyl]-c-hydroxycarbonimidoyl}butanoic acid

C18H29N5O11S2 (555.1305)

(3s,6s,9r,13s,17r,18s,18ar)-17,18-dichloro-3-ethyl-1,4,7,11-tetrahydroxy-6-(hydroxymethyl)-13-methyl-9-phenyl-3h,6h,9h,10h,13h,16h,17h,18h,18ah-pyrrolo[1,2-d]1,4,7,10,13-pentaazacyclohexadecan-14-one

C24H31Cl2N5O6 (555.1651)

(4s,5s,6s)-6-[(r)-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-4,5-dihydroxy-n-[(3s)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-5,6-dihydro-4h-pyran-2-carboximidic acid

(4s,5s,6s)-6-[(r)-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl](c-hydroxycarbonimidoyl)methoxy]-4,5-dihydroxy-n-[(3s)-2-hydroxy-4,5,6,7-tetrahydro-3h-azepin-3-yl]-5,6-dihydro-4h-pyran-2-carboximidic acid

C22H29N5O12 (555.1813)

17,18-dichloro-3-ethyl-1,4,7,11-tetrahydroxy-6-(hydroxymethyl)-13-methyl-9-phenyl-3h,6h,9h,10h,13h,16h,17h,18h,18ah-pyrrolo[1,2-d]1,4,7,10,13-pentaazacyclohexadecan-14-one

C24H31Cl2N5O6 (555.1651)

(e,2z)-2-{[(2s)-2-amino-1-hydroxy-3-(3,4,5-trihydroxyphenyl)propylidene]amino}-3-(3,4,5-trihydroxyphenyl)-n-[(1e)-2-(3,4,5-trihydroxyphenyl)ethenyl]prop-2-enimidic acid

C26H25N3O11 (555.1489)